- Home
- CEV vs TLSA Comparison
CEV vs TLSA Comparison
Compare CEV & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- TLSA
- Stock Information
- Founded
- CEV 1999
- TLSA 2013
- Country
- CEV United States
- TLSA United Kingdom
- Employees
- CEV N/A
- TLSA N/A
- Industry
- CEV Finance/Investors Services
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- TLSA Health Care
- Exchange
- CEV Nasdaq
- TLSA Nasdaq
- Market Cap
- CEV 75.9M
- TLSA 87.8M
- IPO Year
- CEV N/A
- TLSA 2000
- Fundamental
- Price
- CEV $10.41
- TLSA $0.95
- Analyst Decision
- CEV
- TLSA
- Analyst Count
- CEV 0
- TLSA 0
- Target Price
- CEV N/A
- TLSA N/A
- AVG Volume (30 Days)
- CEV 19.6K
- TLSA 408.6K
- Earning Date
- CEV 01-01-0001
- TLSA 12-27-2024
- Dividend Yield
- CEV 4.23%
- TLSA N/A
- EPS Growth
- CEV N/A
- TLSA N/A
- EPS
- CEV 0.36
- TLSA N/A
- Revenue
- CEV N/A
- TLSA N/A
- Revenue This Year
- CEV N/A
- TLSA N/A
- Revenue Next Year
- CEV N/A
- TLSA N/A
- P/E Ratio
- CEV $29.36
- TLSA N/A
- Revenue Growth
- CEV N/A
- TLSA N/A
- 52 Week Low
- CEV $8.83
- TLSA $0.41
- 52 Week High
- CEV $10.91
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- CEV 39.72
- TLSA 49.61
- Support Level
- CEV $10.36
- TLSA $0.88
- Resistance Level
- CEV $10.44
- TLSA $1.03
- Average True Range (ATR)
- CEV 0.07
- TLSA 0.09
- MACD
- CEV 0.01
- TLSA 0.00
- Stochastic Oscillator
- CEV 19.70
- TLSA 20.55
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.